Single-dose piracetam effects on global complexity measures of human spontaneous multichannel EEG

International Journal of Psychophysiology

Volumn 34, Issue 1, 1999, Pages 81-87

  Kondakor, Istvan ^a,b   Michel, Christoph M ^c   Wackermann, Jiri ^d   Koenig, Thomas ^a   Tanaka, Hideaki ^a   Peuvot, Jacques ^e   Lehmann, Dietrich ^a,d  

^a University of Zurich Brain Research Institute   (Switzerland)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Faculty of Medicine   (Switzerland)

^d Institute for Frontier Areas of Psychology and Mental Health   (Germany)

^e UCB PHARMA   (Belgium)

Author keywords

Brain dynamics; EEG state space; Global dimensional complexity; Global omega complexity; Human multichannel EEG; Piracetam effects; Single dose piracetam

Indexed keywords

NOOTROPIC AGENT; PIRACETAM; PLACEBO;

ADULT; BRAIN FUNCTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYNAMICS; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; MALE; MULTICHANNEL RECORDER; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; NOOTROPIC AGENTS; PIRACETAM;

EID: 0032872010     PISSN: 01678760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8760(99)00044-6     Document Type: Conference Paper

References (34)

1. Chiarenza G.A., Grioni A.G., Ragaini C., Guareschi-Gazzullo A. Effect of piracetam on sensorimotor and cognitive processes. Bakker D., Wilsher C., Debruyne H., Bertin N. Development of Dyslexia and Learning Disorders. 1987;91-94 Karger, Basel.
2. Conners C.K., Reader M.J., Reiss A. et al. The effects of piracetam upon visual event-related potentials in dyslexic children. Psychophysiology. 24:1987;513-521.
3. Dvorak I. Takens versus multichannel reconstruction in EEG correlation exponent estimates. Phys. Lett. A. 151:1990;225-233.
4. Friston K.J. Theoretical neurobiology and schizophrenia. Br. Med. Bull. 52:1996;644-655.
5. Giurgea C. The 'nootropic' approach to the pharmacology in neurointegrative activity of the brain. Cond. Reflex. 8:1973;108-115.
6. Gouliaev A.H., Senning A. Piracetam and other structurally related nootropics. Brain Res. Rev. 19:1994;180-222.
7. Heiss W.D., Ilsen H.W., Wagner R., Pawlik G., Wienhard K. Remote functional depression of glucose metabolism in stroke and its alteration by activating drugs. Heiss D., Phelps M.E. Positron Emission Tomography of the Brain. 1983;162-168 Springer, Berlin.
8. Itil T.M. The neurophysiological models in the development of psychotropic hormones. Itil T.M., Laudahn G., Herrmann W.M. Psychotropic Action of Hormones. 1976;53-77 Spectrum Publications, New York.
9. Kinoshita T., Saito A., Yamamoto Y. et al. Computer-assisted EEG study of nootropic drug effects on cerebral function. Takahashi R., Flor-Henry P., Gruzelier J.H., Niwa S.I. Cerebral Dynamics, Laterality and Psychopathology. 1987;125-132 Elsevier, Amsterdam.
10. Koukkou M., Lehmann D., Wackermann J., Dvorak I., Henggeler B. Dimensional complexity of EEG brain mechanisms in untreated schizophrenia. Biol. Psychiatry. 33:1993;397-407.
11. Lehmann D. Multichannel topography of human alpha EEG fields. Electroenceph. Clin. Neurophysiol. 31:1971;439-449.
12. Lehmann D., Wackermann J., Michel C.M., Koenig T. Space-oriented EEG segmentation reveals changes in brain electric field maps under the influence of a nootropic drug. Psychiatry Res. Neuroimaging. 50:1993;275-282.
13. Lopes da Silva F., Pijn J.P., Wadman W.J. Dynamics of local neuronal networks: control parameter and state bifurcation in epileptogenesis. Prog. Brain. Res. 102:1994;359-370.
14. Michel C.M., Lehmann D. Single doses of piracetam affect event-related potential microstates during cognitive information processing. Neuropsychobiology. 28:1993;212-221.
15. Molle M., Pietrowsky R., Fehm H.L., Born J. Regulation of human thought by neuropeptide ACTH 4-10: an analysis of the EEG's dimensional complexity. Neuroreport. 8:1997;2715-2720.
16. Müller W.E., Hartmann H., Koch S., Scheuer K., Stoll S. Neurotransmission in aging-therapeutic aspects. Racagni G., Brunello N., Langer S.Z. Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction, Int. Acad. Biomed. Drug Res. 7:1994;166-173 Karger, Basel.
17. Noble S., Benfield P. Piracetam, a review of its clinical potential in the management of patients with stroke. CNS Drugs. 9:1998;497-511.
18. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 9:1970;97-113.
19. Pedata F., Moroni F., Pepeu G.C. Effect of nootropic agents on brain cholinergic mechanisms. Clin. Neuropharmacol. 7(Suppl. 1):1984;S416.
20. Pede J.P., Schimpfessel L., Grokaert R. The action of piracetam on the oxidative phosphorylation. Arch. Int. Physiol. Biochem. 79:1971;1036.
21. Peuvot J., Schanck A., Deleers M., Brasseur R. Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. Biochem. Pharmacol. 50:1995;1129-1134.
22. Pilch H., Müller W.E. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology. 94:1988;74-78.
23. Pritchard W.S., Duke D.W., Coburn K.L. Altered EEG dynamical responsivity associated with normal aging and probable Alzheimer's disease. Dementia. 2:1991;102-105.
24. Rapp P.E., Bashore T.R., Martinerie J.M., Albano A.M., Zimmerman I.D., Mees A.I. Dynamics of brain electrical activity. Brain Topogr. 2:1989;99-118.
25. Saletu B. EEG imaging of brain activity in clinical psychopharmacology. Maurer K. Topographic Brain Mapping of EEG and Evoked Potentials. 1989;482-506 Springer, Berlin.
26. Sannita W.G., Balestra V., Rosadini G., Salama M., Timitilli C. Quantitative EEG and neuropsychological effects of piracetam and of the association piracetam-lecithin in healthy volunteers. Neuropsychobiology. 14:1985;203-209.
27. Saito N., Kuginuki T., Yagyu T. et al. Global, regional and local measures of complexity of multichannel EEG in acute, neuroleptic-naive, first-break schizophrenics. Biol. Psychiatry. 43:1998;794-802.
28. Schultz D.P. The human subject in psychological research. Psychol. Bull. 72:1969;214-228.
29. Szelenberger W., Wackermann J., Skalski M., Niemcewicz S., Drojewski J. Analysis of complexity of EEG during sleep. Acta Neurobiol. Exp. 56:1996;165-169.
30. Vernon M.W., Sorkin E.M. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drug Aging. 1:1991;17-35.
31. Wackermann J. Beyond mapping: estimating complexity of multichannel EEG recordings. Acta Neurobiol. Exp. 56:1996;197-208.
32. Wackermann J., Lehmann D., Dvorak I., Michel C.M. Global dimensional complexity of multi-channel EEG indicates change of human brain functional state after a single dose of a nootropic drug. Electroenceph. Clin. Neurophysiol. 86:1993;193-198.
33. Wurtman R.J., Fernstrom J.D. Control of brain neurotransmitter synthesis by precursor availability and nutritional state. Biochem. Pharmacol. 25:1976;1691-1696.
34. Yagyu T., Wackermann J., Kinoshita T. et al. Chewing gum flavor affects measures of global complexity of multichannel EEG. Neuropsychobiology. 35:1997;46-50.